Alnylam Pharmace. buy Jefferies Financial Group Inc.
Start price
07.07.25
/
50%
€273.90
Target price
07.07.26
€326.17
Performance (%)
-3.72%
Price
30.04.26
€263.70
Summary
This prediction is currently active. With a performance of -3.72%, the BUY prediction by Jefferies_Financial_ is trending in the wrong direction. This prediction currently runs until 07.07.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -1.824% | -1.824% |
| iShares Core DAX® | 0.985% | 8.314% |
| iShares Nasdaq 100 | 2.067% | 16.765% |
| iShares Nikkei 225® | 2.270% | 15.605% |
| iShares S&P 500 | 1.043% | 11.077% |
Comments by Jefferies_Financial_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Jefferies Financial Group Inc. from $328.00 to $384.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Jefferies_Financial_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€389.00
30.10.25
30.10.25
€472.69
30.10.26
30.10.26
-32.21%
30.04.26
30.04.26
